KR20210113271A - 콜라게나제 제형 및 이의 제조 방법 - Google Patents

콜라게나제 제형 및 이의 제조 방법 Download PDF

Info

Publication number
KR20210113271A
KR20210113271A KR1020217024557A KR20217024557A KR20210113271A KR 20210113271 A KR20210113271 A KR 20210113271A KR 1020217024557 A KR1020217024557 A KR 1020217024557A KR 20217024557 A KR20217024557 A KR 20217024557A KR 20210113271 A KR20210113271 A KR 20210113271A
Authority
KR
South Korea
Prior art keywords
formulation
collagenase
lyophilized
lys
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217024557A
Other languages
English (en)
Korean (ko)
Inventor
카루나카르 스쿠루
Original Assignee
엔도 글로벌 에스테틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔도 글로벌 에스테틱스 리미티드 filed Critical 엔도 글로벌 에스테틱스 리미티드
Priority to KR1020267010947A priority Critical patent/KR20260051486A/ko
Publication of KR20210113271A publication Critical patent/KR20210113271A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020217024557A 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법 Ceased KR20210113271A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267010947A KR20260051486A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788916P 2019-01-06 2019-01-06
US62/788,916 2019-01-06
PCT/US2020/012202 WO2020142701A1 (en) 2019-01-06 2020-01-03 Collagenase formulations and methods of producing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267010947A Division KR20260051486A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
KR20210113271A true KR20210113271A (ko) 2021-09-15

Family

ID=69845512

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217024557A Ceased KR20210113271A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법
KR1020267010947A Pending KR20260051486A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267010947A Pending KR20260051486A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Country Status (10)

Country Link
US (3) US20220305094A1 (cg-RX-API-DMAC10.html)
EP (1) EP3906014A1 (cg-RX-API-DMAC10.html)
JP (2) JP7565280B2 (cg-RX-API-DMAC10.html)
KR (2) KR20210113271A (cg-RX-API-DMAC10.html)
CN (1) CN113382714A (cg-RX-API-DMAC10.html)
AU (2) AU2020204922B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021012675A2 (cg-RX-API-DMAC10.html)
IL (2) IL321891A (cg-RX-API-DMAC10.html)
MX (1) MX2021008017A (cg-RX-API-DMAC10.html)
WO (1) WO2020142701A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172070A1 (ko) * 2022-03-08 2023-09-14 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN114264633B (zh) * 2022-02-10 2022-09-06 上海蓝长科技集团有限公司 一种福尔马肼聚合物冻干粉及制备方法
WO2026094005A1 (en) * 2024-11-04 2026-05-07 Endo Biologics Limited Compositions comprising collagenase for use in treatment of plantar fasciitis
CN119656117B (zh) * 2024-12-18 2025-08-29 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
KR20080071192A (ko) * 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
EP2130551B1 (en) * 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US10119131B2 (en) 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
JP2014530873A (ja) * 2011-10-21 2014-11-20 オーキシリウム インターナショナル ホールディングス，インコーポレイテッド Ｅｆｐの治療または低減方法
EP4772625A2 (en) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
CN110022855B (zh) * 2016-10-07 2024-07-16 瑞泽恩制药公司 室温稳定的冻干蛋白质
DK3589204T3 (da) * 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172070A1 (ko) * 2022-03-08 2023-09-14 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법
US12516310B2 (en) 2022-03-08 2026-01-06 CONNEXT Co., Ltd Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase

Also Published As

Publication number Publication date
IL284270A (en) 2021-08-31
EP3906014A1 (en) 2021-11-10
JP7855655B2 (ja) 2026-05-08
US20240041993A1 (en) 2024-02-08
AU2020204922A1 (en) 2021-07-01
US12303557B2 (en) 2025-05-20
IL284270B2 (en) 2025-12-01
JP2022516569A (ja) 2022-02-28
AU2025204915A1 (en) 2025-07-24
CA3125007A1 (en) 2020-07-09
KR20260051486A (ko) 2026-04-16
US20250249080A1 (en) 2025-08-07
JP7565280B2 (ja) 2024-10-10
CN113382714A (zh) 2021-09-10
US20220305094A1 (en) 2022-09-29
MX2021008017A (es) 2021-08-05
IL284270B1 (en) 2025-08-01
AU2020204922B2 (en) 2025-04-24
BR112021012675A2 (pt) 2021-09-28
IL321891A (en) 2025-09-01
JP2025016453A (ja) 2025-02-04
WO2020142701A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
US12303557B2 (en) Collagenase formulations and methods of producing the same
JP6258674B2 (ja) クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
TW202535466A (zh) 抗-il-23p19抗體調配物
Hackl et al. Effect of arginine on the aggregation of protein in freeze-dried formulations containing sugars and polyol: 1—formulation development
AU2021250949A1 (en) Liquid Pharmaceutical Composition
Bjelošević et al. Effects of monoclonal antibody concentration and type of bulking agent on critical quality attributes of lyophilisates
TWI827694B (zh) 免疫蛋白酶體抑制劑調配物
CA3125007C (en) Collagenase formulations and methods of producing the same
HK40053714A (en) Collagenase formulations and methods of producing the same
US20250235515A1 (en) Clostridium botulinum neurotoxin serotype a compositions and improved drying processes
JP2023526024A (ja) Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)